Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone and sugammadex reversal of rocuronium neuromuscular blockade
ACTRN12612000245897Phase 4Recruiting
- Sponsor
- University Medical Centre Ljubljana
- Start
- Feb 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Sugammadex, dexamethasone, rocuronium and granisetron in neuromuscular block (NMB) (2 arms), sponsored by University Medical Centre Ljubljana. Primary endpoint: Time to full neuromuscular recovery by TOF. Started Feb 2012; status: recruiting.
02
Drugs
Sugammadexdexamethasonerocuroniumgranisetron
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on ACTRN12612000245897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000245897.